International Journal of Psychiatry in Clinical Practice最新文献

Agomelatine bears promising potential in treating bipolar depression- a systematic review.

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-12-19 DOI: 10.1080/13651501.2024.2436177

Junyao Li, Huirong Luo, Qinghua Luo

{"title":"Agomelatine bears promising potential in treating bipolar depression- a systematic review.","authors":"Junyao Li, Huirong Luo, Qinghua Luo","doi":"10.1080/13651501.2024.2436177","DOIUrl":"https://doi.org/10.1080/13651501.2024.2436177","url":null,"abstract":"Introduction: The controversy of antidepressant use in bipolar depression remains controversial. Agomelatine (AGO) is an effective antidepressant in major depressive disorder (MDD), but its application in bipolar depression was little discussed. We aimed to provide a comprehensive systematic review of clinical evidence from studies examining the efficacy and safety of AGO for bipolar depression.Methods: We conducted a systematic review about AGO trials for the treatment of bipolar patients. We searched PubMed, MEDLINE, Embase, and Cochrane for relevant studies published since each database's inception. We synthesised evidence regarding efficacy (mood and rhythm) and tolerability across studies.Results: We identified 6 studies including 272 participants (44% female). All studies used 25-50 mg AGO per day for treatment combined or not combined with mood stabilisers (MS). Across all 6 studies, there were improvements in depression evaluated by depression rating scores and response rate over time. The response rates varied from 43% to 91% within 6-12 weeks. Although AGO was found of better efficacy in bipolar depression compared to recurrent depression, its efficacy remains controversial. Most studies have shown AGO to be effective after just about a week. AGO was reasonably well tolerated both in acute and extension period, without obvious risk in inducing mood switching.Conclusion: AGO is promising in treating bipolar depression with significant efficacy and well tolerability. However, more strictly designed and large-sample trials are needed in further research with homogeneity within intervention and treatment groups.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-9"},"PeriodicalIF":2.9,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevalence, demographics, and clinical characteristics of suicide attempts in first episode drug-naïve schizophrenia patients with comorbid severe depression. 合并严重抑郁症的首次发作药物过敏型精神分裂症患者自杀未遂的发生率、人口统计学特征和临床特征。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-12-10 DOI: 10.1080/13651501.2024.2438754

Jinfeng Zhu, Xiaoe Lang, Fangfang Shangguan, Xiang Yang Zhang

{"title":"Prevalence, demographics, and clinical characteristics of suicide attempts in first episode drug-naïve schizophrenia patients with comorbid severe depression.","authors":"Jinfeng Zhu, Xiaoe Lang, Fangfang Shangguan, Xiang Yang Zhang","doi":"10.1080/13651501.2024.2438754","DOIUrl":"https://doi.org/10.1080/13651501.2024.2438754","url":null,"abstract":"Background: Suicide attempts have been intensively examined in chronic schizophrenia (SCZ) patients with comorbid depression. This study aimed to investigate the prevalence and clinical correlates of suicide attempts in Chinese first episode drug-naïve (FEDN) SCZ patients with comorbid severe depression.Methods: Totally 317 FEDN SCZ patients were recruited into the study. Patients were assessed for symptoms using the 24-item Hamilton Depression Scale (HAMD24), the Hamilton Anxiety Scale (HAMA), and the Positive and Negative Syndrome Scale (PANSS). Plasma glucose and lipids were measured. A score of more than 35 on the HAMD24 was defined as severe depression.Results: Suicide attempts occurred at a higher rate in patients with severe depression than in those without (33.4% vs 16.7%). Among patients with severe depression, HAMD and PANSS total score were higher in suicide attempters compared to non-attempters (all p < 0.05). PANSS total score was independently related to suicide attempts in FEDN SCZ patients who had severe depression (OR = 1.02, p < 0.05).Conclusion: Suicide attempts are more prevalent in FEDN SCZ patients with comorbid severe depression than in those without. Psychotic symptoms might be involved in suicide attempts in FEDN SCZ patients with severe depression, while depressive symptoms might not.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-7"},"PeriodicalIF":2.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating psychiatric morbidity, hopelessness and suicide risk in patients with 22q11.2 deletion syndrome: a case-control study. 调查 22q11.2 缺失综合征患者的精神病发病率、绝望感和自杀风险：一项病例对照研究。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-11-18 DOI: 10.1080/13651501.2024.2427624

Isabella Berardelli, Mariarosaria Cifrodelli, Salvatore Sarubbi, Carlotta Giuliani, Giulia Antonelli, Fabrizio Schirripa, Carolina Putotto, Federica Pulvirenti, Marco Innamorati, Maurizio Pompili

{"title":"Investigating psychiatric morbidity, hopelessness and suicide risk in patients with 22q11.2 deletion syndrome: a case-control study.","authors":"Isabella Berardelli, Mariarosaria Cifrodelli, Salvatore Sarubbi, Carlotta Giuliani, Giulia Antonelli, Fabrizio Schirripa, Carolina Putotto, Federica Pulvirenti, Marco Innamorati, Maurizio Pompili","doi":"10.1080/13651501.2024.2427624","DOIUrl":"https://doi.org/10.1080/13651501.2024.2427624","url":null,"abstract":"Background: The psychiatric phenotype of the 22q11.2 deletion syndrome (22q11DS) has been largely described.Objectives: With a case-control study design, we now compared a sample of 22q11DS patients with a psychiatric diagnosis with a sample of psychiatric patients without 22q11DS to investigate possible differences between groups for depression severity, hopelessness, and suicide. Patients with 22q11DS were divided into two groups according to the levels of hopelessness to evaluate the relationship between hopelessness and the severity of the 22q11DS, the level of disability, functional impairment, physical frailty, and autonomy level.Results: Results showed that suicide risk evaluated with the C-SSRS was similar in the two groups of patients and that a diagnosis of 22q11DS does not appear to be a risk factor for suicide; however, 22q11DS patients had more severe hopelessness. Patients with a more severe clinical presentation and worse overall functioning have higher levels of depressive symptoms and hopelessness.Conclusions: The results suggest the need to assess and monitor psychiatric symptoms in patients with 22q11DS.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"1-6"},"PeriodicalIF":2.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142647687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world outcomes of long-term use of silexan in patients with anxiety disorders: a single-centre experience. 焦虑症患者长期服用西乐葆的实际效果：单中心经验。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-08-18 DOI: 10.1080/13651501.2024.2391301

Sergio Marchevsky

{"title":"Real-world outcomes of long-term use of silexan in patients with anxiety disorders: a single-centre experience.","authors":"Sergio Marchevsky","doi":"10.1080/13651501.2024.2391301","DOIUrl":"10.1080/13651501.2024.2391301","url":null,"abstract":"Objective: To evaluate the effectiveness and safety of long-term use of silexan in patients with a wide range of anxiety disorders.Methods: A retrospective chart review was conducted on 50 patients diagnosed with various anxiety disorders who were prescribed silexan. The primary outcomes measured included the resolution of anxiety symptoms, changes in Generalized Anxiety Disorder-7 (GAD-7) scores, and Clinical Global Impressions-Improvement (CGI-I) scores. The duration of silexan use and any reported adverse events were also recorded.Results: Silexan effectively resolved anxiety symptoms in 35 patients, with 24 out of 25 patients who received silexan for more than 12 weeks showing significant improvement. Median GAD-7 and CGI-I scores decreased significantly (p<0.001). By the end of the follow-up period, 46% of patients had minimal anxiety and 24% had mild anxiety. No adverse events were reported during the study period.Conclusions: Long-term use of silexan is feasible, safe, and effective in managing a wide range of anxiety disorders in real-world clinical settings.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"138-141"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. 开始使用艾司氯胺酮鼻喷雾剂的难治性抑郁症患者的真实人口统计学和临床概况。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-09-02 DOI: 10.1080/13651501.2024.2398788

Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt, Anne Sauvaget, Marie-Alix Codet, Émeline Gaudré-Wattinne, Clotilde Wicart, Maud Rothärmel

{"title":"Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray.","authors":"Ludovic Samalin, Lila Mekaoui, Pierre De Maricourt, Anne Sauvaget, Marie-Alix Codet, Émeline Gaudré-Wattinne, Clotilde Wicart, Maud Rothärmel","doi":"10.1080/13651501.2024.2398788","DOIUrl":"10.1080/13651501.2024.2398788","url":null,"abstract":"Objective: ESKALE is a French, multicentre, observational study of adults with treatment-resistant depression (TRD) treated with esketamine. This interim analysis describes baseline demographic and clinical characteristic evolution in patients included and treated from early access program to post-marketing launch.Methods: Data were collected from medical records and included patient characteristics, disease history at esketamine initiation, use of neurostimulation, the patient's care pathway, and the number of antidepressant treatment lines prescribed prior to esketamine initiation. Descriptive statistics were used for each cohort: the early access program 'Temporary Authorisation for Use' (ATU), post-ATU, and post-launch cohorts.Results: The overall ESKALE cohort (N = 160 included; n = 157 treated with esketamine; average age 49.0 years; 66.2% female) demonstrated moderate-to-severe depression according to clinical assessment and a mean Montgomery-Åsberg Depression Rating Scale score of 32.6 (8.0); however, severity, subtype, and comorbidities were heterogeneous across the cohorts. Earlier use of esketamine and prior to alternative treatments occurred during the later cohorts.Conclusion: These findings demonstrated a high burden of TRD in these patients and that esketamine is used in TRD treatment regardless of their disease severity, subtype, or existing comorbidities. These results also suggest that esketamine is potentially a clinically useful alternative treatment, particularly with healthcare professionals gaining greater familiarity with and easier access to esketamine.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"83-93"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to treat subsyndromal anxiety disorder - practical recommendations for implementation in primary care. 如何治疗亚综合征焦虑症--在初级保健中实施的实用建议。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-06-22 DOI: 10.1080/13651501.2024.2362131

Daniel Lucas da Conceição Costa, Rodolfo Furlan Damiano, José Ángel Alcalá, Martin Hatzinger, Francisco Mesa, Giampaolo Perna, György Purebl, Péter Torzsa, Věra Vobořilová, Peter Zwanzger, Roger Ho, Borwin Bandelow

{"title":"How to treat subsyndromal anxiety disorder - practical recommendations for implementation in primary care.","authors":"Daniel Lucas da Conceição Costa, Rodolfo Furlan Damiano, José Ángel Alcalá, Martin Hatzinger, Francisco Mesa, Giampaolo Perna, György Purebl, Péter Torzsa, Věra Vobořilová, Peter Zwanzger, Roger Ho, Borwin Bandelow","doi":"10.1080/13651501.2024.2362131","DOIUrl":"10.1080/13651501.2024.2362131","url":null,"abstract":"Background: Anxiety is a common and disabling condition that significantly impacts quality of life. Subsyndromal anxiety (SSA) refers to anxiety symptoms that do not meet the full diagnostic criteria for an anxiety disorder but pose a risk for developing such disorders. We aimed to provide practical recommendations for the treatment of SSA in primary care settings.Methods: A narrative review was conducted to identify strategies for recognizing and treating patients with SSA.Results: The recommendations for treating SSA include lifestyle modifications such as exercise and stress reduction techniques, psychotherapy, and pharmacological treatments, including natural compounds like the lavender oil extract Silexan. Regular follow-up care is essential to monitor treatment response and address ongoing symptoms. Additionally, the use of the GAD-7 tool is recommended for accurately identifying patients with SSA.Conclusion: Implementing these recommendations in primary care can lead to effective treatment of SSA, preventing the development of more severe anxiety disorders. An integrative approach, combining lifestyle modifications, psychotherapy, and pharmacotherapy, including natural compounds, offers significant benefits for managing anxiety.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"128-137"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Borderline personality disorder is an innate empathy anomaly: a scoping and narrative review. 边缘型人格障碍是与生俱来的移情异常：范围界定和叙述性综述。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-10-29 DOI: 10.1080/13651501.2024.2420662

David Hayward, Donald MacIntyre, Douglas Steele

{"title":"Borderline personality disorder is an innate empathy anomaly: a scoping and narrative review.","authors":"David Hayward, Donald MacIntyre, Douglas Steele","doi":"10.1080/13651501.2024.2420662","DOIUrl":"10.1080/13651501.2024.2420662","url":null,"abstract":"Background: Studying empathy in borderline personality disorder (BPD) is essential because difficulties with interpersonal functioning are integral.Objectives: This scoping and narrative review explores the aetiological theory that BPD is an innate anomaly of cognitive empathy, with a normal or heightened emotional empathy.Eligibility criteria and sources of evidence: Ovid MEDLINE(R) ALL was searched using the terms empathy; theory of mind; mentalisation or mentalising; borderline empathy; emotion recognition and BPD. For inclusion in the scoping review, articles needed to empirically assess an empathic skill in people with BPD, or self-reported empathy in a BPD group compared to controls, or empathic skill as a 'borderline feature' in a nonclinical sample.Charting method: The results of empirical studies were categorised as per their methodological approach, with results in the BPD group reported as comparable, enhanced or reduced compared to controls.Results: 320 articles were returned, with 38 eligible. The majority affirmed that people with BPD have an anomalous empathetic ability, especially a deficient cognitive empathy. Furthermore, this is trait, evident early in development, correlates with syndrome severity, and is mediated by atypical neural networks.Conclusions: This substantiates the theory that BPD is, at least in major part, an innate empathy anomaly.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"152-166"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lipid variability in drug-naïve individuals affected with Major Depressive Disorder: a systematic review and meta-analysis. 重度抑郁症患者的血脂变异性：系统综述和荟萃分析。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-11-15 DOI: 10.1080/13651501.2024.2427617

Behzad Ensan, Zeinab Sadat Hosseini, Mohammad Mirzaei, Hakime Ghadiri Hakim, Nima Zafari, Tannaz Jamialahmdi, Amirhossein Sahebkar

{"title":"Lipid variability in drug-naïve individuals affected with Major Depressive Disorder: a systematic review and meta-analysis.","authors":"Behzad Ensan, Zeinab Sadat Hosseini, Mohammad Mirzaei, Hakime Ghadiri Hakim, Nima Zafari, Tannaz Jamialahmdi, Amirhossein Sahebkar","doi":"10.1080/13651501.2024.2427617","DOIUrl":"10.1080/13651501.2024.2427617","url":null,"abstract":"Background: This study aimed to provide a comprehensive synthesis of the evidence examining lipid profiles in drug-naïve MDD patients.Materials and methods: We searched PubMed, Scopus, and ISI Web of Science up to August 2023 for total cholesterol, HDL-C, LDL-C, and triglyceride levels in drug-naïve MDD patients.Results: A total of 17 articles comprising 2174 individuals including drug-naïve MDD subjects and controls were included. Our results showed that concentrations of total cholesterol were lower in drug-naïve MDD patients compared with healthy controls (SMD -0.49, 95% CI -0.881 to -0.105; p = 0.015; I2 = 90.6%). However, comparison of other lipid levels between MDD patients and healthy controls demonstrated no significant difference. The results revealed that the association of total cholesterol levels with MDD is more prominent in male-dominant studies (SMD -1.20, 95% CI -2.23 to -0.18, I2 = 87.9%) than in female-dominant studies (SMD -0.25, 95% CI -0.63-0.13, I2 = 89.0%). In meta-regression, none of the factors including year of publication, Newcastle-Ottawa Scale score, sample size, BMI, and mean age of participants had a significant influence on the association between cholesterol levels and MDD.Conclusions: Lower levels of total cholesterol, especially in males, are associated with MDD, so early lipid monitoring and targeted interventions are necessary.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"177-187"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142638961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mirtazapine blood levels and antidepressant response. 米氮平的血药浓度和抗抑郁反应。

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-09-28 DOI: 10.1080/13651501.2024.2409654

Domenico De Donatis, Marco Verrastro, Giuseppe Fanelli, Chiara Fabbri, Ignazio Maniscalco, Xenia Hart, Georgios Schoretsanitis, Laura Mercolini, Raffaele Ferri, Bartolo Lanuzza, Alessandro Serretti, Andreas Conca, Vincenzo Florio

{"title":"Mirtazapine blood levels and antidepressant response.","authors":"Domenico De Donatis, Marco Verrastro, Giuseppe Fanelli, Chiara Fabbri, Ignazio Maniscalco, Xenia Hart, Georgios Schoretsanitis, Laura Mercolini, Raffaele Ferri, Bartolo Lanuzza, Alessandro Serretti, Andreas Conca, Vincenzo Florio","doi":"10.1080/13651501.2024.2409654","DOIUrl":"10.1080/13651501.2024.2409654","url":null,"abstract":"Objective: Therapeutic drug monitoring (TDM) is an important tool for treatment optimisation. Its usefulness has recently been demonstrated for some first-line antidepressants; however, few studies have been reported on the relationship between blood levels of mirtazapine and its antidepressant effects. The aim of this study was to investigate the association between blood concentration of mirtazapine and antidepressant response.Methods: 59 outpatients treated with mirtazapine for depression were recruited and followed up for three months in a naturalistic setting. Hamilton Depression Rating Scale-21 (HAMD-21) was administered at baseline, month 1, and month 3 to assess antidepressant response. Mirtazapine serum concentration was measured at steady state. Linear regression analysis and nonlinear least-squares regression were used to estimate association between serum concentration of mirtazapine and antidepressant response.Results: Our results showed no overall association between serum concentration of mirtazapine and symptom improvement at month 1 and month 3. A marginally significantly higher serum concentration of mirtazapine was found in responders vs non-responders at month 3.Conclusions: The study suggests that serum concentration of mirtazapine is not strongly associated with the antidepressant efficacy of mirtazapine. This is probably attributed to its pharmacodynamic profile, even though higher blood levels seem to be marginally more effective.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"102-106"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unexpected improvement in nicotine consumption after low-frequency repetitive magnetic stimulation. 低频重复磁刺激后尼古丁消耗量的意外改善

IF 2.9 4区医学

International Journal of Psychiatry in Clinical Practice Pub Date : 2024-06-01 Epub Date: 2024-10-17 DOI: 10.1080/13651501.2024.2417651

Ismail Rammouz, Omar El Oumary, Rachid Aalouane, Zouhayr Souirti, Said Boujraf

{"title":"Unexpected improvement in nicotine consumption after low-frequency repetitive magnetic stimulation.","authors":"Ismail Rammouz, Omar El Oumary, Rachid Aalouane, Zouhayr Souirti, Said Boujraf","doi":"10.1080/13651501.2024.2417651","DOIUrl":"10.1080/13651501.2024.2417651","url":null,"abstract":"Background: We report a case on the efficiency of low-frequency repetitive transcranial magnetic stimulation (rTMS) on cigarette consumption cessation.The patient was 29 years old, He received intensive psychiatric treatments along with ten years of history of depressive and obsessive-compulsive disorders.The first four years of treatment were marked by good outcomes. However, the last 6 years were marked by persisting depressive symptoms associating with psychotic features and sexual obsessions.Methods: The patient received 20 sessions of rTMS over two weeks, 10 times per week at 1 Hz frequency, each session lasted 20 min with 200 pulses and 100% of motor threshold. In the meanwhile, the patient continued his full drug-based treatment according to the reported prescription.Results and conclusion: After 20 sessions, the patient reported a decreased severity of his depressive symptoms with a BDI (Beck Depression Inventory) score of 6 but without significant improvement of OCD with a YBOCS score of 32. However, the patient reported great improvement in his tobacco craving and a diminishing number of consumed cigarettes in the second week of the rTMS protocol of treatment. This ended with tobacco cessation within a month. However, this occurred without any medication or psychological support for treating tobacco dependence.","PeriodicalId":14351,"journal":{"name":"International Journal of Psychiatry in Clinical Practice","volume":" ","pages":"142-144"},"PeriodicalIF":2.9,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0